237 related articles for article (PubMed ID: 33529588)
1. Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye Disease.
Clark D; Tauber J; Sheppard J; Brady TC
Am J Ophthalmol; 2021 Jun; 226():22-31. PubMed ID: 33529588
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease.
Clark D; Sheppard J; Brady TC
J Ocul Pharmacol Ther; 2021 May; 37(4):193-199. PubMed ID: 33450164
[No Abstract] [Full Text] [Related]
3. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
[TBL] [Abstract][Full Text] [Related]
4. A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study.
Sheppard JD; Wirta DL; McLaurin E; Boehmer BE; Ciolino JB; Meides AS; Schlüter T; Ousler GW; Usner D; Krösser S
Cornea; 2021 Oct; 40(10):1290-1297. PubMed ID: 34481407
[TBL] [Abstract][Full Text] [Related]
5. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.
Amparo F; Dastjerdi MH; Okanobo A; Ferrari G; Smaga L; Hamrah P; Jurkunas U; Schaumberg DA; Dana R
JAMA Ophthalmol; 2013 Jun; 131(6):715-723. PubMed ID: 23599118
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.
Akpek EK; Wirta DL; Downing JE; Tauber J; Sheppard JD; Ciolino JB; Meides AS; Krösser S
JAMA Ophthalmol; 2023 May; 141(5):459-466. PubMed ID: 37022717
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
[TBL] [Abstract][Full Text] [Related]
8. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
[TBL] [Abstract][Full Text] [Related]
9. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
[TBL] [Abstract][Full Text] [Related]
10. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
[TBL] [Abstract][Full Text] [Related]
11. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.
Sosne G; Dunn SP; Kim C
Cornea; 2015 May; 34(5):491-6. PubMed ID: 25826322
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement.
Mandell KJ; Clark D; Chu DS; Foster CS; Sheppard J; Brady TC
J Ocul Pharmacol Ther; 2020 Dec; 36(10):732-739. PubMed ID: 32955967
[No Abstract] [Full Text] [Related]
13. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.
Tauber J; Davitt WF; Bokosky JE; Nichols KK; Yerxa BR; Schaberg AE; LaVange LM; Mills-Wilson MC; Kellerman DJ
Cornea; 2004 Nov; 23(8):784-92. PubMed ID: 15502479
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease.
Tauber J; Wirta DL; Sall K; Majmudar PA; Willen D; Krösser S;
Cornea; 2021 Sep; 40(9):1132-1140. PubMed ID: 33369937
[TBL] [Abstract][Full Text] [Related]
15. Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial.
Clark D; Cavanagh B; Shields AL; Karpecki P; Sheppard J; Brady TC
Am J Ophthalmol; 2021 Oct; 230():60-67. PubMed ID: 33945820
[TBL] [Abstract][Full Text] [Related]
16. Effects of corneal nerve density on the response to treatment in dry eye disease.
Kheirkhah A; Dohlman TH; Amparo F; Arnoldner MA; Jamali A; Hamrah P; Dana R
Ophthalmology; 2015 Apr; 122(4):662-8. PubMed ID: 25542519
[TBL] [Abstract][Full Text] [Related]
17. Reduced Efficacy of Low-dose Topical Steroids in Dry Eye Disease Associated With Graft-versus-Host Disease.
Yin J; Kheirkhah A; Dohlman T; Saboo U; Dana R
Am J Ophthalmol; 2018 Jun; 190():17-23. PubMed ID: 29572107
[TBL] [Abstract][Full Text] [Related]
18. A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease.
Schmidl D; Szalai L; Kiss OG; Schmetterer L; Garhöfer G
Adv Ther; 2021 Apr; 38(4):1975-1986. PubMed ID: 33710587
[TBL] [Abstract][Full Text] [Related]
19. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.
Tauber J; Berdy GJ; Wirta DL; Krösser S; Vittitow JL;
Ophthalmology; 2023 May; 130(5):516-524. PubMed ID: 36574848
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
Evans D; Kenyon K; Ousler G; Watson M; Vollmer P; McLaurin EB; Torkildsen G; Winters J; Dodd J; Jordan R; Wills ST; Spana C
J Ocul Pharmacol Ther; 2023 Nov; 39(9):600-610. PubMed ID: 37677000
[No Abstract] [Full Text] [Related]
[Next] [New Search]
